Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 208

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 208
---
     | $: RMB |     |      |  7.2994 |     |      |  7.0971 |     |      |  6.9091 |
| Period average |     | $: RMB |     |      |  7.1946 |     |      |  7.0835 |     |      |  6.4569 |

Cash and cash equivalents
include cash on hand, deposits held at call with financial institutions, other short-term deposits with original maturities of three months
or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

Deposits, other receivables
and deferred Initial Public Offering (“IPO”) cost, net primarily include deposits paid to suppliers, prepaid expenses, the
prepaid professional fee which meets the definition of deferred IPO cost, and a cash deposit of US$1,000,000 with OSL Group, a digital
asset trading platform listed in Hong Kong Stock Exchange, for the Company’s future digital asset diversification strategy.

Deferred IPO costs consist
of underwriting, legal, accounting and other expenses incurred through the balance sheet date that are directly related to the Initial
Public Offering and that were charged to additional paid-in capital upon the completion of the Initial Public Offering.

Legal and professional fees
incurred in connection with issuing convertible debt are deferred and amortized over the life of the debt. These costs are presented
as a direct deduction from the carrying amount of the debt liability on the balance sheet (per ASC 835-30).

The Company accounts for
stock-based compensation in accordance with ASC Topic 718-10, Compensation-Stock Compensation, which requires the measurement
and recognition of compensation expense for all share-based payment arrangements related to the acquisition of goods and services from
both nonemployees and employees based on fair values of the shares to be issued estimated at grant date. The stock-based compensation
expense recognized during the period is based on the value of the portion of share-based payment awards that is ultimately expected to
vest during the period.

<div align='center'>F-13</div>

Fair value is determined
based on the estimated market prices of the Company’s Common Stock at the respective issuance date in accordance with ASC 718,
taking into consideration the volatility of the market price of the shares, the terms of the instruments and the conditions upon which
they were granted.

Plant and equipment are
stated at cost less accumulated depreciation